{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T15:24:34Z","timestamp":1774538674478,"version":"3.50.1"},"reference-count":53,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The aim of this review is to discuss current diagnostic approaches to, and classification of, patients presenting with thrombocytosis, in light of novel information derived from the discovery of specific molecular abnormalities in chronic myeloproliferative disorders (CMPD), which represent the most common cause of primary thrombocytosis. The JAK2V617F and the MPLW515L\/K mutations have been found in patients with essential thrombocythemia, polycythemia vera, and primary myelofibrosis, and less frequently in other myeloproliferative disorders complicated by thrombocytosis. However, neither mutation is disease specific nor is it universally present in patients with elevated platelet counts due to a CMPD; therefore, distinguishing between reactive and primary forms of thrombocytosis, as well as among the different clinical entities that constitute the CMPD, still requires a multifaceted diagnostic approach that includes as a key step the accurate evaluation of bone marrow histology. The role of elevated platelet counts in thrombosis, which represent the predominant complication of CMPD,significantly affecting prognosis and quality of life as well as, paradoxically, in the pathogenesis of the hemorrhagic manifestations, will be discussed. Established and novel potential risk factors for thrombosis, including the clinical relevance of the JAK2V617F mutation, and current management strategies for thrombocytosis are also briefly discussed.<\/jats:p>","DOI":"10.1182\/asheducation-2007.1.363","type":"journal-article","created":{"date-parts":[[2007,11,16]],"date-time":"2007-11-16T13:08:40Z","timestamp":1195218520000},"page":"363-370","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":68,"title":["Thrombocytosis and Thrombosis"],"prefix":"10.1182","volume":"2007","author":[{"given":"Alessandro M.","family":"Vannucchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziano","family":"Barbui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111702042594500_R1","doi-asserted-by":"crossref","unstructured":"Schafer AI. Thrombocytosis. N Engl J Med. 2004;350:1211\u20131219.","DOI":"10.1056\/NEJMra035363"},{"key":"2019111702042594500_R2","doi-asserted-by":"crossref","unstructured":"Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest. 2005;115:3339\u20133347.","DOI":"10.1172\/JCI26674"},{"key":"2019111702042594500_R3","doi-asserted-by":"crossref","unstructured":"Kaushansky K. On the molecular origins of the chronic myeloproliferative disorders: it all makes sense. Blood. 2005;105:4187\u20134190.","DOI":"10.1182\/blood-2005-03-1287"},{"key":"2019111702042594500_R4","doi-asserted-by":"crossref","unstructured":"Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med. 2006;355:2452\u20132466.","DOI":"10.1056\/NEJMra063728"},{"key":"2019111702042594500_R5","doi-asserted-by":"crossref","unstructured":"Schafer AI. Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood. 2006;107:4214\u20134222.","DOI":"10.1182\/blood-2005-08-3526"},{"key":"2019111702042594500_R6","doi-asserted-by":"crossref","unstructured":"Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350:114\u2013124.","DOI":"10.1056\/NEJMoa035572"},{"key":"2019111702042594500_R7","doi-asserted-by":"crossref","unstructured":"Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353:33\u201345.","DOI":"10.1056\/NEJMoa043800"},{"key":"2019111702042594500_R8","doi-asserted-by":"crossref","unstructured":"Dame C, Sutor AH. Primary and secondary thrombocytosis in childhood. Br J Haematol. 2005;129:165\u2013177.","DOI":"10.1111\/j.1365-2141.2004.05329.x"},{"key":"2019111702042594500_R9","doi-asserted-by":"crossref","unstructured":"Ruggeri M, Tosetto A, Frezzato M, Rodeghiero F. The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis. Ann Intern Med. 2003;139:470\u2013475.","DOI":"10.7326\/0003-4819-139-6-200309160-00009"},{"key":"2019111702042594500_R10","doi-asserted-by":"crossref","unstructured":"Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110:1092\u20131097.","DOI":"10.1182\/blood-2007-04-083501"},{"key":"2019111702042594500_R11","doi-asserted-by":"crossref","unstructured":"Kralovics R, Skoda RC. Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders. Blood Rev. 2005;19:1\u201313.","DOI":"10.1016\/j.blre.2004.02.002"},{"key":"2019111702042594500_R12","doi-asserted-by":"crossref","unstructured":"Moliterno AR, Williams DM, Gutierrez-Alamillo LI, Salvatori R, Ingersoll RG, Spivak JL. Mpl Baltimore: a thrombopoietin receptor polymorphism associated with thrombocytosis. Proc Natl Acad Sci U S A. 2004;101:11444\u201311447.","DOI":"10.1073\/pnas.0404241101"},{"key":"2019111702042594500_R13","doi-asserted-by":"crossref","unstructured":"James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144\u20131148.","DOI":"10.1038\/nature03546"},{"key":"2019111702042594500_R14","doi-asserted-by":"crossref","unstructured":"Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054\u20131061.","DOI":"10.1016\/S0140-6736(05)71142-9"},{"key":"2019111702042594500_R15","doi-asserted-by":"crossref","unstructured":"Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387\u2013397.","DOI":"10.1016\/j.ccr.2005.03.023"},{"key":"2019111702042594500_R16","doi-asserted-by":"crossref","unstructured":"Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779\u20131790.","DOI":"10.1056\/NEJMoa051113"},{"key":"2019111702042594500_R17","doi-asserted-by":"crossref","unstructured":"Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3:e270.","DOI":"10.1371\/journal.pmed.0030270"},{"key":"2019111702042594500_R18","doi-asserted-by":"crossref","unstructured":"Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108:3472\u20133476.","DOI":"10.1182\/blood-2006-04-018879"},{"key":"2019111702042594500_R19","doi-asserted-by":"crossref","unstructured":"Guglielmelli P, Pancrazzi A, Bergamaschi G, et al. Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. Br J Haematol. 2007;137:244\u2013247.","DOI":"10.1111\/j.1365-2141.2007.06565.x"},{"key":"2019111702042594500_R20","doi-asserted-by":"crossref","unstructured":"Vainchenker W, Constantinescu SN. A unique activating mutation in JAK2 (V617F) Is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases. Hematology Am Soc Hematol Educ Program. 2005:195\u2013200.","DOI":"10.1182\/asheducation-2005.1.195"},{"key":"2019111702042594500_R21","doi-asserted-by":"crossref","unstructured":"Levine RL, Wernig G. Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders. Hematology Am Soc Hematol Educ Program. 2006:233\u2013239.","DOI":"10.1182\/asheducation-2006.1.233"},{"key":"2019111702042594500_R22","doi-asserted-by":"crossref","unstructured":"Ingram W, Lea NC, Cervera J, et al. The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow. Leukemia. 2006;20:1319\u20131321.","DOI":"10.1038\/sj.leu.2404215"},{"key":"2019111702042594500_R23","doi-asserted-by":"crossref","unstructured":"Randi ML, Putti MC, Scapin M, et al. Pediatric patients with essential thrombocythemia are mostly polyclonal and V617FJAK2 negative. Blood. 2006;108:3600\u20133602.","DOI":"10.1182\/blood-2006-04-014746"},{"key":"2019111702042594500_R24","doi-asserted-by":"crossref","unstructured":"Teofili L, Giona F, Martini M, et al. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia. J Clin Oncol. 2007;25:1048\u20131053.","DOI":"10.1200\/JCO.2006.08.6884"},{"key":"2019111702042594500_R25","doi-asserted-by":"crossref","unstructured":"Moliterno AR, Williams DM, Rogers O, Spivak JL. Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression. Blood. 2006;108:3913\u20133915.","DOI":"10.1182\/blood-2006-03-008805"},{"key":"2019111702042594500_R26","doi-asserted-by":"crossref","unstructured":"Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292\u20132302.","DOI":"10.1182\/blood-2002-04-1199"},{"key":"2019111702042594500_R27","doi-asserted-by":"crossref","unstructured":"Tefferi A, Vardiman JW. The diagnostic interface between histology and molecular tests in myeloproliferative disorders. Curr Opin Hematol. 2007;14:115\u2013122.","DOI":"10.1097\/MOH.0b013e32801684d9"},{"key":"2019111702042594500_R28","doi-asserted-by":"crossref","unstructured":"Thiele J, Kvasnicka HM. A critical reappraisal of the WHO classification of the chronic myeloproliferative disorders. Leuk Lymphoma. 2006;47:381\u2013396.","DOI":"10.1080\/10428190500331329"},{"key":"2019111702042594500_R29","doi-asserted-by":"crossref","unstructured":"Michiels JJ, Berneman Z, Van Bockstaele D, van der Planken M, De Raeve H, Schroyens W. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications. Semin Thromb Hemost. 2006;32:174\u2013207.","DOI":"10.1055\/s-2006-939431"},{"key":"2019111702042594500_R30","doi-asserted-by":"crossref","unstructured":"Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2005;128:275\u2013290.","DOI":"10.1111\/j.1365-2141.2004.05277.x"},{"key":"2019111702042594500_R31","doi-asserted-by":"crossref","unstructured":"Harrison CN. Platelets and thrombosis in myeloproliferative diseases. Hematology Am Soc Hematol Educ Program. 2005:409\u2013415.","DOI":"10.1182\/asheducation-2005.1.409"},{"key":"2019111702042594500_R32","doi-asserted-by":"crossref","unstructured":"Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23:2224\u20132232.","DOI":"10.1200\/JCO.2005.07.062"},{"key":"2019111702042594500_R33","doi-asserted-by":"crossref","unstructured":"Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical profile of homozygous JAK2V617F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007;110:840\u2013846.","DOI":"10.1182\/blood-2006-12-064287"},{"key":"2019111702042594500_R34","doi-asserted-by":"crossref","unstructured":"Di Nisio M, Barbui T, Di Gennaro L, et al. The haematocrit and platelet target in polycythemia vera. Br J Haematol. 2007;136:249\u2013259.","DOI":"10.1111\/j.1365-2141.2006.06430.x"},{"key":"2019111702042594500_R35","doi-asserted-by":"crossref","unstructured":"Cervantes F, Alvarez-Larran A, Arellano-Rodrigo E, Granell M, Domingo A, Montserrat E. Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institution. Leukemia. 2006;20:55\u201360.","DOI":"10.1038\/sj.leu.2404048"},{"key":"2019111702042594500_R36","doi-asserted-by":"crossref","unstructured":"Streiff MB, Smith B, Spivak JL. The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of American Society of Hematology members\u2019 practice patterns. Blood. 2002;99:1144\u20131149.","DOI":"10.1182\/blood.V99.4.1144"},{"key":"2019111702042594500_R37","doi-asserted-by":"crossref","unstructured":"Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol. 2005;33:523\u2013530.","DOI":"10.1016\/j.exphem.2005.01.015"},{"key":"2019111702042594500_R38","doi-asserted-by":"crossref","unstructured":"Mesa RA, Nagorney DS, Schwager S, Allred J, Tefferi A. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer. 2006;107:361\u2013370.","DOI":"10.1002\/cncr.22021"},{"key":"2019111702042594500_R39","doi-asserted-by":"crossref","unstructured":"Finazzi G, Barbui T. Risk-adapted therapy in essential thrombocythemia and polycythemia vera. Blood Rev. 2005;19:243\u2013252.","DOI":"10.1016\/j.blre.2005.01.001"},{"key":"2019111702042594500_R40","unstructured":"Barbui T, Barosi G, Grossi A, et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica. 2004;89:215\u2013232."},{"key":"2019111702042594500_R41","doi-asserted-by":"crossref","unstructured":"Landolfi R, Di Gennaro L, Barbui T, et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood. 2007;109:2446\u20132452.","DOI":"10.1182\/blood-2006-08-042515"},{"key":"2019111702042594500_R42","doi-asserted-by":"crossref","unstructured":"Carobbio A, Finazzi G, Guerini V, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood. 2007;109:2310\u20132313.","DOI":"10.1182\/blood-2006-09-046342"},{"key":"2019111702042594500_R43","doi-asserted-by":"crossref","unstructured":"Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995;332:1132\u20131136.","DOI":"10.1056\/NEJM199504273321704"},{"key":"2019111702042594500_R44","doi-asserted-by":"crossref","unstructured":"Finazzi G, Rambaldi A, Guerini V, Carobbo A, Barbui T. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica. 2007;92:135\u2013136.","DOI":"10.3324\/haematol.10634"},{"key":"2019111702042594500_R45","doi-asserted-by":"crossref","unstructured":"Antonioli E, Guglielmelli P, Pancrazzi A, et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia. 2005;19:1847\u20131849.","DOI":"10.1038\/sj.leu.2403902"},{"key":"2019111702042594500_R46","doi-asserted-by":"crossref","unstructured":"Kittur J, Knudson RA, Lasho TL, et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer. 2007;109:2279\u20132284.","DOI":"10.1002\/cncr.22663"},{"key":"2019111702042594500_R47","doi-asserted-by":"crossref","unstructured":"Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005;366:1945\u20131953.","DOI":"10.1016\/S0140-6736(05)67785-9"},{"key":"2019111702042594500_R48","doi-asserted-by":"crossref","unstructured":"Vannucchi AM, Antonioli E, Guglielmelli P, et al. Prospective identification of high-risk polycythemia vera patients based on JAK2 V617F allele burden. Leukemia. 2007;21:1952\u20131959.","DOI":"10.1038\/sj.leu.2404854"},{"key":"2019111702042594500_R49","doi-asserted-by":"crossref","unstructured":"Finazzi G, Barbui T. How I treat patients with polycythemia vera. Blood. 2007;109:5104\u20135111.","DOI":"10.1182\/blood-2006-12-038968"},{"key":"2019111702042594500_R50","doi-asserted-by":"crossref","unstructured":"Barbui T, Finazzi G. When and how to treat essential thrombocythemia. N Engl J Med. 2005;353:85\u201386.","DOI":"10.1056\/NEJMe058093"},{"key":"2019111702042594500_R51","doi-asserted-by":"crossref","unstructured":"Tefferi A. Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era. Hematology Am Soc Hematol Educ Program. 2006:240\u2013245.","DOI":"10.1182\/asheducation-2006.1.240"},{"key":"2019111702042594500_R52","doi-asserted-by":"crossref","unstructured":"Barosi G, Besses C, Birgegard G, et al. A unified definition of clinical resistance\/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. Leukemia. 2007;21:277\u2013280.","DOI":"10.1038\/sj.leu.2404473"},{"key":"2019111702042594500_R53","doi-asserted-by":"crossref","unstructured":"Barbui T, Finazzi G. Myeloproliferative disease in pregnancy and other management issues. Hematology Am Soc Hematol Educ Program. 2006:246\u2013252.","DOI":"10.1182\/asheducation-2006.1.246"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2007\/1\/363\/646258\/363_370ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2007\/1\/363\/646258\/363_370ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T02:04:51Z","timestamp":1573956291000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2007\/1\/363\/19181\/Thrombocytosis-and-Thrombosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1,1]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2007.1.363","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1,1]]}}}